163 related articles for article (PubMed ID: 30542710)
1. miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2.
Yin Y; Liu H; Xu J; Shi D; Zhai L; Liu B; Wang L; Liu G; Qin J
Oncol Rep; 2018 Dec; 40(6):3479-3488. PubMed ID: 30542710
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
3. miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway.
Shi L; Chen ZG; Wu LL; Zheng JJ; Yang JR; Chen XF; Chen ZQ; Liu CL; Chi SY; Zheng JY; Huang HX; Lin XY; Zheng F
Asian Pac J Cancer Prev; 2014; 15(23):10439-44. PubMed ID: 25556489
[TBL] [Abstract][Full Text] [Related]
4. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
5. 4-methoxychalcone enhances cisplatin-induced oxidative stress and cytotoxicity by inhibiting the Nrf2/ARE-mediated defense mechanism in A549 lung cancer cells.
Lim J; Lee SH; Cho S; Lee IS; Kang BY; Choi HJ
Mol Cells; 2013 Oct; 36(4):340-6. PubMed ID: 24046186
[TBL] [Abstract][Full Text] [Related]
6. miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.
Zhao Z; Zhang L; Yao Q; Tao Z
Cancer Gene Ther; 2015 Apr; 22(3):108-14. PubMed ID: 25721211
[TBL] [Abstract][Full Text] [Related]
7. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
8. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.
Bao L; Wu J; Dodson M; Rojo de la Vega EM; Ning Y; Zhang Z; Yao M; Zhang DD; Xu C; Yi X
Mol Carcinog; 2017 Jun; 56(6):1543-1553. PubMed ID: 28112439
[TBL] [Abstract][Full Text] [Related]
9. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
10. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.
Qiu T; Zhou L; Wang T; Xu J; Wang J; Chen W; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
Int J Mol Med; 2013 Sep; 32(3):593-8. PubMed ID: 23856992
[TBL] [Abstract][Full Text] [Related]
11. Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression.
Wu J; Zhang L; Li H; Wu S; Liu Z
Biochem Biophys Res Commun; 2019 Oct; 518(4):698-705. PubMed ID: 31472965
[TBL] [Abstract][Full Text] [Related]
12. The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells.
Silva MM; Rocha CRR; Kinker GS; Pelegrini AL; Menck CFM
Sci Rep; 2019 Nov; 9(1):17639. PubMed ID: 31776385
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Qin X; Yu S; Zhou L; Shi M; Hu Y; Xu X; Shen B; Liu S; Yan D; Feng J
Int J Nanomedicine; 2017; 12():3721-3733. PubMed ID: 28553110
[TBL] [Abstract][Full Text] [Related]
15. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.
Homma S; Ishii Y; Morishima Y; Yamadori T; Matsuno Y; Haraguchi N; Kikuchi N; Satoh H; Sakamoto T; Hizawa N; Itoh K; Yamamoto M
Clin Cancer Res; 2009 May; 15(10):3423-32. PubMed ID: 19417020
[TBL] [Abstract][Full Text] [Related]
16. miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8.
Zhang Z; Zhang L; Yin ZY; Fan XL; Hu B; Wang LQ; Zhang D
Int J Clin Exp Pathol; 2014; 7(10):7236-41. PubMed ID: 25400821
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer.
Chen Y; Gao Y; Zhang K; Li C; Pan Y; Chen J; Wang R; Chen L
Cell Physiol Biochem; 2015; 37(5):1869-80. PubMed ID: 26584286
[TBL] [Abstract][Full Text] [Related]
18. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
Huang RS; Zheng YL; Zhao J; Chun X
Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
[TBL] [Abstract][Full Text] [Related]
19. Wilms' tumor 1 enhances Cisplatin-resistance of advanced NSCLC.
Wu C; Wang Y; Xia Y; He S; Wang Z; Chen Y; Wu C; Shu Y; Jiang J
FEBS Lett; 2014 Dec; 588(24):4566-72. PubMed ID: 25447528
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
Guo L; Liu Y; Bai Y; Sun Y; Xiao F; Guo Y
Eur J Cancer; 2010 Jun; 46(9):1692-702. PubMed ID: 20371173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
